TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Body fat measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic Syndrome Components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioural Correlate of Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Correlate of Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac Correlates of Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen Saturation Correlate of Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy Success
Endpoint domain: Mortality/survival
Primary endpoint: Presumptive Clinical Cure Score (PCCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sensitivity to thermal stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection rate of malignant biliary stricture diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: presence of dyskinesias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alteration of the clavicle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastric antral cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number and percent of patients experiencing a treatment emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration, time of maximum plasma concentration and area under the concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of typical symptoms of intussusceptions and bloody stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 42-day PCR-adjusted parasitological cure of P. falciparum parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Trough Morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in free testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in 17-hydroxyprogesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequencies of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with abnormal and clinically significant judged by investigator for electrocardiogram measurements
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who meet the markedly abnormal criteria for safety laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: salivary bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in panic scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Daily Workbook Entries Completed
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: CNS Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Young Mania Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Severe AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: HIV Medication Adherence (% Adherent)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Asynchrony percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFO closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Difference of Glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference of Insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference of appetite hormones levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of molecular response 4.5 (MR4.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Surveillance time prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Negative predictive value of diminutive polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of WASP classification in histological prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: complete epithelization of diabetic foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hernia Recurrence Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinematics of lower limbs articulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effect on T cell tumor infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Closure of Patent Ductus Arteriosus (PDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emotional Recognition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progress of lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Global Impression-improvement scale responders percentage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression in diabetic retinopathy staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-Traumatic Stress Disorder Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of anti-CMV therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnosis of CMV pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Renal uptake measured by 111In-exendin-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in Hemoglobin of ≥1.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C at Week 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Long Head of the Biceps Tendon Score (LHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Oxford knee score (OKS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postural stability as assessed by force plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NF-kB activity p65
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fat Free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of sacrospinous ligaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pathological Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anaesthetic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative gain in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Events Severity and Frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility based on compliance with TTFields therapy
Endpoint domain: Resource use
Primary endpoint: Procedure Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of Postpartum Depression
Endpoint domain: Adverse events/effects
Primary endpoint: t1/2,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood perfusion change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Joint stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stiffness of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognitive Assessment Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Normal values for depolarization characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amikacin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye-tracking Score: Phase Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye-tracking Score: Tangential and Radial Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye-tracking Score: Vertical and Horizontal Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tone in splenius capitis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in 24-hr proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Primary Accuracy Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed virologic response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Brain-specific progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for endoscopic sphincterotomy (ES) before self-expanding metal stent (SEMS) placement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event-related evoked potentials (ERPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: necrosis/viable tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of immune infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degrees of inflammation, fibrosis, and mucin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate in para-aortic lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Variation of visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The time of total duration of ICU stay
Endpoint domain: Resource use
Primary endpoint: Domestic assault recidivism
Endpoint domain: Mortality/survival
Primary endpoint: Conflict Tactics Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of dermal irritability and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of wrinkles grade around the eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of dark circles grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of roughness profilometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Assessment in Dry Eye (SANDE) Symptoms Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrent VH Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Perceived effects of Brief Admission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With TEAEs by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Food Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective Appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: % reduction in drain fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence Rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tardieu scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurocognitive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chronic Pain: Pain Catastrophizing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sleep Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of Patient Disposition Decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disease activity score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Re-intubation Within 72 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency Department Recidivism
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Left Ventricular End Diastolic Volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 Minutes Hall Walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary artery hypertension (PAH)-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of psychiatric hospitalization days in the year following NAVIGATE admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to first psychiatric hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of clinical psychopathology [PHQ-9]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective reaction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of lenalidomide plus conventional chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: TcCO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of MRSA Colonization or Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Tidal variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of local allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: detection of associated thoracic injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of clinical and radiological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon monoxide (CO)-validated continuous abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Leicester Cough Questionnaire (LCQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-operative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Status Outcome at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Status Outcome at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Resolution of signs and symptoms of scorpion envenomation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volemia evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Causally Related Treatment-emergent SAEs and AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Moderate or Severe TEAEs That May be a Result of Immune-Mediated Responses
Endpoint domain: Adverse events/effects
Primary endpoint: Complication free rate of all SIELLO leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular threshold of SIELLO T (passive fixation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial threshold of SIELLO S (active fixation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical reorganization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in gut microbiota diversity and relative abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) Rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in liver fat content (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Urine Output at 24 Hours Post Randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of surgical blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Eventual conversion to open surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of EPCs in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diabetic neuropathy pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of site-specific defects within the lateral vaginal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the plasma drug concentration-time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FACT-Ntx score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Speech-language outcome score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular CDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration for Melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve AUC(0-t) of Melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes